MicroRNA-24 aggravates atherosclerosis by inhibiting selective lipid uptake from HDL cholesterol via the post-transcriptional repression of scavenger receptor class B type I

Ren, Kewei; Zhu, Xiao Feng; Zheng, Zhoushun; Zhang, Mo; Peng, Xiaoshan; Zeng, Yanhua; Ou, Han-Xiao; Zhang, Qinghai; Qi, Huizhou; Zhao, Guo-Jun; Yi, Guanghui

doi:10.1016/j.atherosclerosis.2018.01.045

Cited by 42 publications

(35 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…miR-223 inhibits genes involved in cholesterol biosynthesis (e.g., 3-Hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and methylsterol monooxygenase 1 (SC4MOL)) and HDL uptake (scavenger receptor-BI, SR-BI), and miR-223 −/− mice have elevated hepatic and plasma total and HDL cholesterol levels [15]. miR-24 has also been shown to aggravate atherosclerosis by inhibiting genes involved in lipogenesis (e.g., insulin-induced gene 1 (INSIG1), an inhibitor of lipogenesis) [16] and HDL uptake (SR-BI) [17]. In vivo, miR-24 administration decreased hepatic SR-BI expression and promoted atheromatous plaque formation in atherosclerotic-prone apolipoprotein E-null (Apoe −/− ) mice [17].…”

Section: Introductionmentioning

confidence: 99%

“…miR-24 has also been shown to aggravate atherosclerosis by inhibiting genes involved in lipogenesis (e.g., insulin-induced gene 1 (INSIG1), an inhibitor of lipogenesis) [16] and HDL uptake (SR-BI) [17]. In vivo, miR-24 administration decreased hepatic SR-BI expression and promoted atheromatous plaque formation in atherosclerotic-prone apolipoprotein E-null (Apoe −/− ) mice [17]. Inhibition of miR-486 and miR-92a decreased liver and plasma cholesterol by targeting SREBP1 and ABCG4, respectively [18].…”

Section: Introductionmentioning

confidence: 99%

“…Cholesterol-loaded mature HDL facilitates the removal or redistribution of cholesterol via its uptake in the liver through SR-BI. In atherosclerosis, miR-185, miR-96, miR-223 and miR-24 target hepatic SR-BI to suppress HDL uptake in the liver, preventing cholesterol excretion by the liver [15,17,30,35]. miR-24 was further shown to contribute to plaque progression, promoting lipid accumulation in the liver [17,36].…”

Section: Introductionmentioning

confidence: 99%

“…In atherosclerosis, miR-185, miR-96, miR-223 and miR-24 target hepatic SR-BI to suppress HDL uptake in the liver, preventing cholesterol excretion by the liver [15,17,30,35]. miR-24 was further shown to contribute to plaque progression, promoting lipid accumulation in the liver [17,36]. Overall, these studies demonstrate that multiple miRNAs can contribute to the burden of lipid build-up in the arteries via different mechanisms, and those with multi-faceted effects on these processes represent the most fundamental regulators that likely contribute to disease progression.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis

Solly

Dimasi

Bursill

et al. 2019

JCM

View full text Add to dashboard Cite

Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Atherosclerosis develops over several decades and is mediated by a complex interplay of cellular mechanisms that drive a chronic inflammatory milieu and cell-to-cell interactions between endothelial cells, smooth muscle cells and macrophages that promote plaque development and progression. While there has been significant therapeutic advancement, there remains a gap where novel therapeutic approaches can complement current therapies to provide a holistic approach for treating atherosclerosis to orchestrate the regulation of complex signalling networks across multiple cell types and different stages of disease progression. MicroRNAs (miRNAs) are emerging as important post-transcriptional regulators of a suite of molecular signalling pathways and pathophysiological cellular effects. Furthermore, circulating miRNAs have emerged as a new class of disease biomarkers to better inform clinical diagnosis and provide new avenues for personalised therapies. This review focusses on recent insights into the potential role of miRNAs both as therapeutic targets in the regulation of the most influential processes that govern atherosclerosis and as clinical biomarkers that may be reflective of disease severity, highlighting the potential theranostic (therapeutic and diagnostic) properties of miRNAs in the management of cardiovascular disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis

Solly

Dimasi

Bursill

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…A HDL transporta microRNAs que diminuem a expressão de moléculas de adesão e de receptores de colesterol, mantendo a partícula mais tempo na circulação, contribuindo com a remoção do excesso de colesterol (VICKERS et al 2011;REN et al 2018…”

Section: Lista De Figurasunclassified

Desenvolvimento de um escore de funcionalidade da lipoproteína de alta densidade (HDL) e sua associação com algoritmos de predição de risco cardiovascular e aterosclerose subclínica em indivíduos brasileiros

Freitas¹

View full text Add to dashboard Cite

Introduction: current studies have not presented association between high densitylipoprotein cholesterol (HDL-C) increase, induced by drugs or genetic mutations, and coronary events reduction. HDL plays different functional cardioprotective role. Objective: to develop a HDL functionality score (HFS) and to assessment its association with predictive cardiovascular risk algorithms and subclinical atherosclerosis outcomes in Brazilian subjects. Methods: cross-sectional study based in two steps. In the first step, the HFS predictor of cardiovascular risk disease (HFS-CVR) was developed and validated on CARDIONUTRI study subsample (n=354). In second step the HFS predictor of subclinical atherosclerosis (HFS-SA) was developed and validated on ELSA-Brasil study subsample (n=4549). Conclusion: the HFS demonstrates strong association with cardiovascular risk and subclinical atherosclerosis, independent of HDL-C, with emphasis on large HDL. Controversial results between HDL subfractions and cardiovascular risk seem to maintain a relation with the different methodologies used in the analysis. Therefore, the validation of the methods and the inclusion of the HDL size as a cardiovascular risk marker reveal a promising future as an adjunct in the estimation of cardiovascular risk, drug management and decision making in clinical practice.

show abstract

Scavenger receptor Class B type I as a potential risk stratification biomarker and therapeutic target in cardiovascular disease

Sahebi

Hassanian

Ghayour‐Mobarhan

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the leading cause of mortality globally. There are few useful markers available for CVD risk stratification that has proven clinical utility. Scavenger receptor B type I (SR‐BI) is a cell surface protein that plays a major role in cholesterol homeostasis through its interaction with high‐density lipoprotein‐cholesterol (HDL‐C) esters (CE). HDL delivers CE to the liver through selective uptake by the SR‐BI. SR‐BI also regulates the inflammatory response. It has been shown that SR‐BI overexpression has beneficial, protective effects in atherogenesis, and there is considerable interest in developing antiatherogenic strategies that involve SR‐BI‐mediated increases in reverse cholesterol transport through HDL and/or low‐density lipoprotein. Further investigations are essential to explore the clinical utility of this approach. Moreover, there is growing evidence showing associations between genetic variants with modulation of SR‐BI function that may, thereby, increase CVD risk. The aim of the current review was to provide an overview of the possible molecular mechanisms by which SR‐BI may affect CVD risk, and the clinical implications of this, with particular emphasis on preclinical studies on genetic changes of SR‐BI and CVD risk.

show abstract

MicroRNA-24 aggravates atherosclerosis by inhibiting selective lipid uptake from HDL cholesterol via the post-transcriptional repression of scavenger receptor class B type I

Cited by 42 publications

References 38 publications

MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis

MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis

Desenvolvimento de um escore de funcionalidade da lipoproteína de alta densidade (HDL) e sua associação com algoritmos de predição de risco cardiovascular e aterosclerose subclínica em indivíduos brasileiros

Scavenger receptor Class B type I as a potential risk stratification biomarker and therapeutic target in cardiovascular disease

Contact Info

Product

Resources

About